NervGen Pharma Corp NGENF

Primary Symbol: V.NGEN

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by curious924on Jul 28, 2022 3:05pm

579 Views

Post# 34857864

Incredible news! Unbelievable that this board is not going

I agree with the assessment from the last news release. Best stock out there, but apparently little known. The stock is up nearly 25% and one post about it? Market cap is under $85 million Cnd. But what do we think a repair after a stroke is worth, to say nothing about reversing Alzheimer's, MS, and spinal cord injuries!

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec